These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. Broderick KE; Chan A; Lin F; Shen X; Kichaev G; Khan AS; Aubin J; Zimmermann TS; Sardesai NY Mol Ther Nucleic Acids; 2012 Feb; 1(2):e11. PubMed ID: 23344722 [TBL] [Abstract][Full Text] [Related]
66. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Flingai S; Czerwonko M; Goodman J; Kudchodkar SB; Muthumani K; Weiner DB Front Immunol; 2013 Nov; 4():354. PubMed ID: 24204366 [TBL] [Abstract][Full Text] [Related]
67. Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Mendoza JM; Amante DH; Kichaev G; Knott CL; Kiosses WB; Smith TR; Sardesai NY; Broderick KE Vaccines (Basel); 2013 Aug; 1(3):384-97. PubMed ID: 26344120 [TBL] [Abstract][Full Text] [Related]
69. The viability of DNA vaccines--marcus evans conference. 3-5 February 2004, London, UK. March JB IDrugs; 2004 Mar; 7(3):226-8. PubMed ID: 15017462 [TBL] [Abstract][Full Text] [Related]
70. Quantitative Proteomic Analysis of Cell Responses to Electroporation, a Classical Gene Delivery Approach. Zhao M; Zhao D; Ma Y; Hu Z; Wei Z Proteomics; 2018 Aug; 18(16):e1800127. PubMed ID: 30035351 [TBL] [Abstract][Full Text] [Related]
71. Impedance analysis of adherent cells after in situ electroporation-mediated delivery of bioactive proteins, DNA and nanoparticles in µL-volumes. Stolwijk JA; Wegener J Sci Rep; 2020 Dec; 10(1):21331. PubMed ID: 33288771 [TBL] [Abstract][Full Text] [Related]
72. Revisiting the role of pulsed electric fields in overcoming the barriers to in vivo gene electrotransfer. Sachdev S; Potočnik T; Rems L; Miklavčič D Bioelectrochemistry; 2022 Apr; 144():107994. PubMed ID: 34930678 [TBL] [Abstract][Full Text] [Related]
74. DNA Vaccines 2008--A marcus evans Forum Bridging the Gap Between Technology and Application. Ulmer JB IDrugs; 2008 May; 11(5):322-4. PubMed ID: 18465669 [No Abstract] [Full Text] [Related]
75. Production of research-grade antibody by in vivo electroporation of DNA-encoding target protein. Okahara F; Itoh K; Ebihara M; Kobayashi M; Maruyama H; Kanaho Y; Maehama T Anal Biochem; 2005 Jan; 336(1):138-40. PubMed ID: 15582570 [No Abstract] [Full Text] [Related]
77. "Naked" DNA transfer technology for genetic vaccination against infectious disease. Fazio VM Res Virol; 1997; 148(2):101-8. PubMed ID: 9108608 [No Abstract] [Full Text] [Related]
79. International meeting on the nucleic acid vaccines for the prevention of infectious disease and regulating nucleic acid (DNA) vaccines. Natcher Conference Center NIH, Bethesda, MD 5-8 February, 1996. Spier RE Vaccine; 1996 Sep; 14(13):1285-8. PubMed ID: 8961519 [No Abstract] [Full Text] [Related]
80. Workshop on the control and standardization of nucleic acid vaccines. Bethesda, Maryland, 8 February 1996. Smith HA; Goldenthal KL; Vogel FR; Rabinovich R; Aguado T Vaccine; 1997 Jun; 15(8):931-3. PubMed ID: 9340950 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]